Q-omics provides the consensus-scored CACNG6 profile across patient tissues and cancer cell-line models. CACNG6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CACNG6 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, CACNG6 RNA expression shows 9,045 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, LUSC, and HNSC as cancer lineages where CACNG6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNG6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNG6 survival associations across molecular data types. CACNG6 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNG6 RNA expression–survival associations across cancer types. High CACNG6 expression shows unfavorable associations in KIRC, MESO and OV, but favorable associations in SKCM, CESC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CACNG6 RNA expression.
This table summarizes CACNG6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CACNG6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNG6 shows lower tumor expression in LUSC, LUAD, COAD, HNSC, KICH and KIRC. The LUSC box plot shows higher CACNG6 RNA expression in normal versus tumor tissue (log2 FC = −1.947, t-test p < 0.001).
This table shows molecular features associated with CACNG6 in patient tissues and cancer cell lines. In patient samples, CACNG6 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNG6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
